Residency · Residency · Ophthalmology

Optic Neuritis: Diagnosis, Workup, and Prognosis

Definition and Etiology

Optic neuritis is an inflammatory, demyelinating, or infectious condition of the optic nerve. It is most commonly idiopathic or associated with multiple sclerosis, which is the most common cause in young adults. Other important associations include neuromyelitis optica spectrum disorder (NMOSD), which is characterized by AQP4-IgG antibodies and tends to cause severe, bilateral optic neuritis, and MOG antibody disease (MOGAD), which features anti-MOG antibodies, often bilateral involvement with prominent disc edema, and generally good visual recovery. Infectious etiologies include syphilis, Lyme disease, tuberculosis, post-infectious viral inflammation, and fungal infections. Autoimmune and inflammatory conditions such as sarcoidosis, systemic lupus erythematosus, and vasculitis can also cause optic neuritis. Drug-induced optic neuritis may occur with ethambutol, isoniazid, or linezolid.

Clinical Presentation

Typical Optic Neuritis (MS-Associated)

Typical MS-associated optic neuritis affects patients between the ages of 20 and 45 with a 3:1 female predominance. The presentation is characteristically unilateral, with subacute vision loss developing over hours to days. Pain with eye movement is present in over 90% of cases, caused by inflammation of the optic nerve sheath. Dyschromatopsia -- particularly red desaturation -- is often out of proportion to the degree of visual acuity loss, making it a sensitive clinical sign. A relative afferent pupillary defect is present in unilateral cases. The visual field typically shows a central or cecocentral scotoma, though virtually any field pattern is possible.

In two-thirds of MS-related optic neuritis, the inflammation is retrobulbar, and the optic disc appears entirely normal on examination -- giving rise to the classic teaching that "the patient sees nothing and the doctor sees nothing." In the remaining one-third, disc swelling is present (papillitis), which is more common in children and in MOGAD. The Uhthoff phenomenon -- transient worsening of vision with heat or exercise -- occurs because demyelinated nerve fibers conduct more poorly at elevated temperatures. The Pulfrich phenomenon produces an anomaly of depth perception caused by asymmetric conduction velocity between the two optic nerves.

Optic Neuritis Subtypes

Atypical Features (Red Flags for Non-MS Etiology)

Several features should raise suspicion for a non-MS cause of optic neuritis. These include bilateral simultaneous involvement, absence of pain, severe disc edema with hemorrhages, failure to recover after four to six weeks, progressive worsening beyond two weeks, age over 50 or under 15, systemic symptoms such as fever, rash, or additional neurological signs, and the presence of a macular star pattern, which indicates neuroretinitis and should prompt investigation for infectious causes such as cat-scratch disease or syphilis.

<image>Fundus photographs comparing normal optic disc in retrobulbar optic neuritis, papillitis with disc edema in acute optic neuritis, and neuroretinitis with disc edema and macular star pattern</image>

Diagnostic Workup

Optic Neuritis Treatment Trial (ONTT) -- Key Findings

The ONTT, published in 1992, is the landmark trial that shaped the management of optic neuritis. It compared intravenous methylprednisolone, oral prednisone, and placebo. Intravenous methylprednisolone (250 mg every six hours for three days followed by an oral prednisone taper over eleven days) produced faster visual recovery -- approximately two weeks earlier than placebo -- but did not significantly change the final visual acuity at one year. It also reduced the rate of MS development at two years, though this protective effect was no longer significant at five years. A critical finding was that oral prednisone alone at 1 mg/kg actually increased the recurrence rate of optic neuritis -- a result that established the firm principle that oral steroids alone should never be used. Placebo-treated patients achieved similar final visual outcomes to the IV steroid group at one year.

Imaging

MRI of the brain and orbits with gadolinium enhancement is the essential imaging study. Fat-suppressed T2/STIR sequences demonstrate optic nerve enhancement and thickening. The most important prognostic information comes from the brain MRI: periventricular white matter lesions indicating demyelination are the strongest predictor of MS development. ONTT data showed that patients with one or more white matter lesions on MRI had a 56% risk of developing MS at 10 years, compared with 22% for those with a normal brain MRI. MRI of the spine should be obtained if NMOSD is suspected or if atypical features are present.

Laboratory Studies

For a classic presentation with typical clinical features and MRI findings consistent with MS, extensive laboratory workup may be deferred. When atypical features are present, testing should include AQP4-IgG for NMOSD and MOG-IgG for MOGAD, along with CBC, ESR, CRP, ANA, ANCA, ACE level for sarcoidosis, RPR/VDRL and FTA-ABS for syphilis, Lyme serology, QuantiFERON testing for tuberculosis, and vitamin B12 and folate levels.

OCT

OCT provides objective structural measurements that evolve over the course of optic neuritis. Acutely, RNFL thickening from edema may be present. By three to six months, RNFL thinning develops as axonal loss occurs, with an average loss of 10 to 20 micrometers that correlates with visual function. Thinning of the ganglion cell layer combined with the inner plexiform layer may occur earlier than RNFL thinning and reflects ganglion cell loss.

Differential Diagnosis of Optic Neuritis

NMOSD (Neuromyelitis Optica Spectrum Disorder)

NMOSD is AQP4-IgG seropositive in approximately 80% of cases. It typically produces bilateral, severe optic neuritis with poor visual recovery and is associated with longitudinally extensive transverse myelitis spanning three or more vertebral segments. The risk of severe permanent vision loss is substantially higher than in MS. Acute treatment requires plasma exchange in addition to intravenous methylprednisolone, and relapse prevention employs rituximab, eculizumab, or inebilizumab. Critically, NMOSD must not be treated with MS disease-modifying therapies, as some of these agents can worsen NMOSD.

MOGAD (MOG Antibody Disease)

MOGAD is defined by the presence of anti-MOG antibodies detected on cell-based assay. It is more common in children and young adults and often presents with bilateral optic neuritis and prominent disc edema. MRI characteristically shows perineural enhancement of the optic nerve sheath rather than enhancement of the nerve itself. Visual recovery is generally better than in NMOSD but relapses can occur, and chronic immunosuppression may be needed in relapsing cases. MOGAD is now recognized as a distinct entity, separate from both MS and NMOSD.

Treatment

Acute Management

For typical optic neuritis with a high likelihood of MS, the ONTT protocol of intravenous methylprednisolone is standard: 1 gram daily for three to five days, followed by an oral prednisone taper (though some clinicians omit the taper). This regimen speeds visual recovery but does not alter the final visual outcome. The decision to treat may be individualized: mild cases with preserved visual acuity can be observed, while treatment is indicated for significant vision loss, bilateral involvement, or occupational need for rapid recovery. In NMOSD-associated optic neuritis, more aggressive treatment is necessary, combining intravenous methylprednisolone with plasma exchange over five to seven cycles. In MOGAD-associated optic neuritis, intravenous methylprednisolone is used with a slow oral taper, as rapid steroid tapering leads to early relapse.

Long-Term MS Prevention

When brain MRI reveals demyelinating white matter lesions, discussion of disease-modifying therapy should be initiated in coordination with neurology. The CHAMPS and CHAMPIONS studies demonstrated that early initiation of interferon therapy reduced the risk of conversion to clinically definite MS. Modern disease-modifying therapies include numerous options such as interferons, glatiramer acetate, fingolimod, natalizumab, and ocrelizumab, among others. The ophthalmologist's role is to diagnose optic neuritis, initiate acute treatment, and refer to neurology for long-term management and disease-modifying therapy decisions.

<image>MRI of the orbits showing optic nerve enhancement on fat-suppressed T1-weighted post-gadolinium sequence in acute optic neuritis, and brain MRI showing periventricular white matter lesions suggesting demyelination</image>

Prognosis

The visual prognosis for typical MS-associated optic neuritis is excellent: 95% of patients recover to 20/40 or better at one year. However, subtle deficits in contrast sensitivity and color vision may persist despite good Snellen acuity recovery. Recurrence occurs in approximately 35% of patients within 10 years, with a higher rate in those who develop MS. The ONTT long-term data showed that 50% of patients developed MS within 15 years of their initial optic neuritis episode. NMOSD carries a poorer prognosis, with cumulative vision loss accruing with each relapse. MOGAD generally affords good acute recovery, but the relapse risk means cumulative damage remains possible over time.

Clinical Pearls

Oral prednisone alone must never be used for optic neuritis, as the ONTT clearly demonstrated that it increases the recurrence rate. Pain with eye movement is the hallmark symptom of optic neuritis, and its absence should prompt consideration of alternative diagnoses. A relative afferent pupillary defect should always be present in unilateral optic neuritis; its absence should raise doubt about the diagnosis. MRI of the brain is the single most important prognostic test for assessing MS risk. AQP4-IgG and MOG-IgG antibodies should be ordered in atypical cases, bilateral optic neuritis, severe vision loss, or when recovery is poor. Neuroretinitis -- optic disc edema with a macular star pattern of exudates -- is not associated with MS and should direct the workup toward infectious causes. Distinguishing NMOSD from MS is critical because their treatments differ fundamentally, and using the wrong therapy can worsen the disease. The Uhthoff phenomenon, in which vision temporarily worsens with heat or exercise, can be a useful historical clue to confirm prior optic neuritis in a patient presenting with vague visual complaints.

References

• Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology. 1997;49(5):1404-1413.
• Beck RW, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis (ONTT). N Engl J Med. 1992;326(9):581-588.
• Jarius S, et al. MOG-IgG in NMO and related disorders: a multicenter study. J Neuroinflammation. 2016;13(1):280.
• Wingerchuk DM, et al. International consensus diagnostic criteria for NMOSD. Neurology. 2015;85(2):177-189.
• American Academy of Ophthalmology. Basic and Clinical Science Course, Section 5: Neuro-Ophthalmology.

Read this lecture as Markdown